Products

What will AGI do for Bamifylline?

This classification denotes a bronchodilator, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier ZTY15D026H. European Medicines Agency schedules Bamifylline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06097MIG. Bamifylline generally arises in the molecular formula C20H27N5O3. The term BAMIFYLLINE is an International Non-Proprietary Name or INN. BAMIFYLLINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule bamifylline under HS 29395900 and SITC 54145. As of Q4 2014, BAMIFYLLINE remains the US FDA Preferred Term for this commodity. Bamifylline bears US NLM identifiers UMLS ID C0052945 and NCI Concept Code C76573. SMILES: O=C1N(C(=O)N(C2NC(N(CCN(CCO)CC)C12)CC1CCCCC1)C)C.

How AGI delivers it

Four ways AGI delivers for Bamifylline

  • Headless SaaS for Agents

    Give your tools an agent-consumable surface (API / MCP / SDK) so agents can do the work.

    For Bamifylline, give your tools an agent-consumable surface (API / MCP / SDK) so agents can do the work.

  • Services-as-Software

    Get the professional outcome delivered as software, priced on results, not headcount.

    For Bamifylline, get the professional outcome delivered as software, priced on results, not headcount.

Value flow

How Bamifylline connects

measured by

  • Assaymodel
  • Assay Puritymodel
  • Chromatographic Impurity Profilemodel
  • Melting Pointmodel
  • Puritymodel